Product
Supplier
Encyclopedia
Inquiry
Home > News > Pharma News > Hikal: Successfully developed Fapiravir APIs and intermediates

Hikal: Successfully developed Fapiravir APIs and intermediates

ECHEMI 2020-06-22

Indian pharmaceutical intermediate and API manufacturer Hikal Limited (Hikal Limited) announced on June 19 that it has successfully developed Favipiravir API and its intermediates.

Fapiravir is a generic drug of Avigan, a drug of Toyama Chemical, a subsidiary of Fujifilm Corporation in Japan. The drug has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of new influenza virus infections. At present, in many countries, piravir is in different stages of clinical trials for the treatment of new coronavirus pneumonia.

It is reported that Hikal is negotiating with potential partners on the supply of the finished medicine.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Looking for chemical products? Let suppliers reach out to you!

Comment
Comment
  • Life Sciences Industry Overview

    The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.
    Published in: June.2026

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.